CAS 18583-89-6

methyl 3-amino-2-methylbenzoate

Codes: LENA-014

Application context (from source-drug indications)

Marginal zone B-cell lymphomaLenalidomideFollicular lymphomaLenalidomideAdult T-cell leukaemia/lymphomaLenalidomideMantle cell lymphomaLenalidomideMyelodysplastic syndromeLenalidomideMultiple myelomaLenalidomide

Source drugs (routes using this intermediate)

Drug	Tier	Expiry
Lenalidomide	Tier B — Position early	-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

LenalidomideProcess routesteps: 5total yield: 63 g

3-amino-2-methylbenzoic acid→methyl 3-amino-2-methylbenzoate→methyl 3-((tert-butoxycarbonyl)amino)-2-methylbenzoate→methyl 2-(bromomethyl)-3-((tert-butoxycarbonyl)amino)benzoate→3-aminopiperidine-2,6-dione hydrochloride→tert-butyl (2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)carbamate

Intermediates available on this site

Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.

Supplier	Product	Price band	MOQ	Lead time	Qualifications	Action
Qualified Partner — East China API Works	methyl 2-(bromomethyl)-3-nitrobenzoate Pharmaceutical Intermediates	On request	On request	On request	—
Unibest Nantong cGMP Site	3-aminopiperidine-2,6-dione hydrochloride Pharmaceutical Intermediates	On request	On request	On request	—

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.